Clinical trial NCT06422949: Efficacy and Safety of HILOTERM® Device for the Prevention of Peripheral Neuropathy
Official title: A Study on the Efficacy and Safety of HILOTERM® Device for the Prevention of Chemotherapy-induced Peripheral Neuropathy in Early Breast Cancer Patients
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Breast Cancer
Neuropathy;Peripheral
Keywords: Early stage breast cancer
Paclitaxel
Chemotherapy-induced peripheral neuropathy
Lead sponsor: European Institute of Oncology
Sponsor class: OTHER
First posted: 2024-05-21
Enrollment: 120
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Taxol is a very effective drug in breast cancer, but it can cause peripheral neuropathy (PN). This toxicity is often dose-limiting. Symptoms of PN usually improve after taxol discontinuation, but \>80% of affected women experience symptoms 1-3 years after treatment stop. The intensity, the duration and the type of symptoms related to PN are very different and they can strongly interfere with patients' quality of life.

The application of cold to the hands and feet seems to be able to reduce the incidence of PN. Hilotherm® is a machine that allows to cool hands and feet. The aim of this study is to verify whether the use of Hilotherm® is able to reduce the incidence of moderate and severe PN and to evaluate the tolerability of Hilotherm® and its impact on quality of life.

Detailed description: Taxol is a very effective drug in breast cancer, but it can cause peripheral neuropathy (PN), that is damage to the nerves of the hands and feet. This toxicity can begin a few days to months after starting taxol treatment and is often dose-limiting.

Symptoms of chemotherapy-induced peripheral neuropathy (CIPN) usually improve after taxol discontinuation, but \>80% of affected women experience symptoms 1-3 years after treatment stop. The intensity, the duration and the type of symptoms related to PN are very different and they range from mild and transient symptoms to more severe and persistent symptoms. These symptoms can strongly interfere with patients' quality of life and can create difficulties in carrying out activities of daily living.

Despite numerous pharmacological approaches, no substance has proven capable of counteracting the onset of PN in patients eligible to receive chemotherapy with taxol. Some clinical studies have shown that the application of cold to the hands and feet is able to reduce the incidence of PN because the cold-induced constriction of the vessels leads to a reduction of blood flow and consequently to a reduced inflow of drug at the level of the hands and feet.

Hilotherm® is a machine that allows to keep hands and feet at a constant temperature of 10°C. The aim of this study is to verify whether the use of Hilotherm® is able to reduce the incidence of moderate and severe PN and to evaluate the tolerability of Hilotherm® and its impact on quality of life.

Eligibility criteria: Inclusion Criteria:

* Women \> 18 years of age
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
* Radically operated infiltrating breast cancer, pT1-T3, pN0-2, M0
* Candidate to adjuvant chemotherapy that includes weekly paclitaxel 80 mg/m2 intravenous for 12 weeks \[either following anthracyclines and/or in association with trastuzumab\]
* Negative pregnancy test at baseline (in fertile women)
* Willing and able to sign informed consent for protocol treatment

Exclusion Criteria:

* Evidence of metastatic disease (M1)
* pT4 and/or pN3
* Previous or concomitant malignancy of any other type
* Previous treatment with chemotherapy, hormonal therapy or an investigational drug for any type of malignancy
* Plans to use a chemotherapy regimen other than those specified in the inclusion criteria
* Any serious concurrent infection or any clinically significant medical illness (in particular clinically significant liver disease, clinically significant renal dysfunction, clinically significant cardiovascular disease, uncontrolled infections) which would jeopardize the ability of the patient to complete the planned therapy and follow-up
* Pre-existing motor or sensory neuropathy of any grade, for any reason
* Participation in any other clinical investigation or exposure to other investigational agents, drugs, device or procedure that may cause PN
* History of Raynaud phenomenon, either primary or secondary to autoimmune or connective tissue diseases such as systemic lupus erythematous, scleroderma, Buerger disease, Sjögren syndrome, rheumatoid arthritis, occlusive vascular disease, such as atherosclerosis, polymyositis, cold agglutinin disease or cryoglobulinemia, thyroid disorders, pulmonary hypertension
* Cold urticaria / cold contact urticaria
* Severe arterial disease
* Trophic tissue lesions
* Diabetes mellitus
* Alcohol abuse
* History of severe allergic, anaphylactic, or other hypersensitivity reactions to the components of Hilotherm Chemo care device
* Simultaneous use of Dignicap system to prevent hair loss from chemotherapy

Primary outcomes:
measure: Overall incidence of grade 2 or 3 CIPN
timeFrame: 12 months
Secondary outcomes:
measure: Incidence of withdrawal from Hilotherapy
timeFrame: 12 weeks
measure: Patients' physical, psychological and social functions evaluation
timeFrame: 12 months
measure: Side effects impact evaluation
timeFrame: 12 months
measure: Pain assessment
timeFrame: 12 months
measure: Technology acceptance and perception evaluation
timeFrame: 12 months
Other outcomes:
Locations:
city: Milan
country: Italy
facility: European Institute of Oncology
Study officials:
affiliation: European Istitute of Oncology
name: Silvia Dellapasqua, MD
role: PRINCIPAL_INVESTIGATOR
References: